Personalized Glioblastoma Vaccine Extends Survival in 9-Patient Phase 1 Trial
Updated
Updated · WashU Medicine · May 12
Personalized Glioblastoma Vaccine Extends Survival in 9-Patient Phase 1 Trial
9 articles · Updated · WashU Medicine · May 12
Nine adults with newly diagnosed glioblastoma received the personalized DNA vaccine GNOS-PV01 after surgery, and the phase 1 trial reported no serious side effects plus broad immune responses in all but one patient.
As many as 40 tumor-specific proteins were targeted per patient—about twice prior cancer vaccines—aiming to prevent the aggressive brain cancer from escaping immune attack and to turn “cold” tumors more immunologically active.
Two-thirds of patients were progression-free at six months and alive at one year, versus roughly 40% historically for this hard-to-treat MGMT-unmethylated subtype; one-third were still alive at two years, about double historical rates.
One participant remains alive and recurrence-free nearly five years after diagnosis, an outlier result that researchers say supports testing the vaccine in larger studies and across more glioblastoma types.
This vaccine 'heats up' tumors for immune attack, but what's to stop the cancer from simply going cold again?
Can a vaccine tailored to one person ever become a widespread, affordable cure for this deadly brain cancer?
Personalized Neoantigen DNA Vaccine GNOS-PV01 Shows Promising Phase 1 Results in Glioblastoma: A New Era for Brain Cancer Immunotherapy
Overview
The report highlights the successful completion of a Phase 1 clinical trial for GNOS-PV01, a highly personalized DNA vaccine designed to fight glioblastoma, an aggressive brain cancer. In this trial, nine newly diagnosed patients received individualized treatment at the Siteman Cancer Center, where each patient was given a unique synthetic DNA molecule tailored to the specific markers on their tumor cells. This approach aims to improve safety and effectiveness by targeting the unique features of each patient’s cancer, marking a significant step forward in personalized medicine and offering new hope for treating glioblastoma.